View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 16, 2019updated 12 Jul 2022 12:23pm

PhaseBio doses first patient in ticagrelor antiplatelet activity trial

US-based clinical-stage biotechnology company PhaseBio Pharmaceuticals has dosed the first patient in a Phase IIb clinical trial of PB2452.

US-based clinical-stage biotechnology company PhaseBio Pharmaceuticals has dosed the first patient in a Phase IIb clinical trial of PB2452.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

PB2452 is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding activities and other surgery situations.

The multi-centred, randomised, double-blind, placebo-controlled Phase IIb trial will evaluate the safety and efficacy of PB2452 in reversing the antiplatelet effects of ticagrelor.

Patients will be on a dual antiplatelet therapy of ticagrelor and low-dose aspirin.

The trial also marks the beginning of US Food and Drug Administration (FDA ) aligned registrational trials to submit the Biologics License Application (BLA) for PB2452 accelerated approval.

The study is expected to involve the participation of approximately 200 subjects aged 50 to 80, resembling the patient population most likely to be treated with ticagrelor and to potentially benefit from PB2452.

Enrolled participants will be randomised in a ratio of 3:1 and will receive either PB2452 or placebo accordingly, with over 150 subjects receiving PB2452.

The primary endpoint of the trial will be achieved upon the reversal of the antiplatelet effects of ticagrelor with intravenous infusion of PB2452 or placebo. The reversal will be measured by the VerifyNow PRUTes biomarker.

PhaseBio Pharmaceuticals chief medical officer John Lee said: “We are pleased that the first patient has been dosed in the registrational Phase IIb clinical trial of PB2452, as it signifies continued progress on our accelerated approval pathway discussed with the FDA at our end-of-phase-one meeting.

“We continue to be encouraged by the potential of PB2452 to address a significant unmet need for patients by reversing the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

“Our plans to initiate our Phase III trial in the first quarter of 2020 and potentially submit a BLA for PB2452 in the second half of 2022 remain on track.”

The company recently completed a Phase IIa trial, with PB2452 achieving immediate and sustained reversal of the antiplatelet effects of ticagrelor in subjects who were put on dual antiplatelet therapy of ticagrelor and low-dose aspirin.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena